ADC Therapeutics SA
ADC Therapeutics SA (ADCT): 13 pipeline candidates · 1 upcoming catalyst · ~25 mo cash runway · 2 clinical trials. Updated within the last hour.
BioSniper Score
6-factor signal · derived from public data
24.7 months
D/E -2.35 · 21% dilution
Lead: Phase 2
13 candidates
1 upcoming, next in ~743d
0 buys · 6 sells (180d)
A transparent, data-derived signal for ADC Therapeutics SAacross cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
$133.6M
Cash
$231.0M
Quarterly Burn
$29.7M
Runway
24.7 mo
Revenue
$20.9M
Cash Runway vs Catalysts
Tracked catalysts land within the current projected cash runway.
Pipeline (13 candidates)
| Drug | Phase |
|---|---|
| adct-241 | Preclinical |
| ADCT-601 | Phase 1 |
| ADCT-602 | Phase 1 |
| CAR T-cells | Phase 2 |
| Etoposide | Phase 2 |
| Etoposide Phosphate | Phase 2 |
| Ifosfamide | Phase 2 |
| Loncastuximab tesirine | Phase 1 |
| mosunetuzumab | Phase 1 |
| obinutuzumab | Phase 1 |
Showing 10 of 13 candidates. Sign up for full pipeline.
Upcoming Catalysts (1)
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
114
Total value held
$177.5M
| Holder | Shares | Value |
|---|---|---|
| prosight management, lp | 8,300,000 | $31.1M |
| blackrock, inc. | 6,250,747 | $23.4M |
| eventide asset management, llc | 5,701,655 | $21.4M |
| morgan stanley | 3,812,582 | $14.3M |
| millennium management llc | 3,254,154 | $12.2M |
| goldman sachs group inc | 1,653,026 | $6.2M |
| state street corp | 1,566,662 | $5.9M |
| bank of america corp /de/ | 1,325,017 | $5.0M |
| orbimed advisors llc | 1,318,026 | $4.9M |
| geode capital management, llc | 1,203,756 | $4.5M |
Showing top 10 of 114 institutional holders of ADC Therapeutics SA. Sign up for the full 13F holder list and quarter-by-quarter ownership history.
Frequently asked questions
How many drug candidates are in ADC Therapeutics SA's pipeline?
ADC Therapeutics SA (ADCT) has 13 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is ADC Therapeutics SA's lead drug candidate?
ADC Therapeutics SA's most advanced tracked candidate is adct-241 (Preclinical) for Metastatic castrate resistant prostate cancer.
What is ADC Therapeutics SA's next catalyst?
ADC Therapeutics SA's next tracked catalyst is a Phase3_Topline event — "Phase 3 Topline: A Phase 3 Randomized Study of Loncastuximab Tesirine Combined With Rituximab Versus Immunochemothera" — expected June 30, 2028.
What is ADC Therapeutics SA's cash runway?
Based on its most recent reported cash balance and quarterly burn rate, ADC Therapeutics SA has approximately 24.7 months of cash runway.
What is ADC Therapeutics SA's market capitalization?
ADC Therapeutics SA's market capitalization is approximately $133.6M.
Get the full picture on ADC Therapeutics SA
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.